Progress of PARP inhibitors in breast cancer
10.3760/cma.j.issn.1006-9801.2019.08.017
- VernacularTitle:PARP抑制剂在乳腺癌中的研究进展
- Author:
Dong LI
1
;
Jun WANG
;
Lijun MA
;
Jinnan GAO
Author Information
1. 山西医学科学院 山西大医院乳腺外科
- Keywords:
Breast neoplasms;
PARP inhibitors
- From:
Cancer Research and Clinic
2019;31(8):573-576
- CountryChina
- Language:Chinese
-
Abstract:
PARP inhibitors are a kind of anticancer drugs approved for the clinical treatment of ovarian cancer and primary peritoneal cancer on the basis of the strategy of synthetic lethality. With the publication of two phase Ⅲ clinical trials results, the indications for PARP inhibitors have been expanded to advanced breast cancer with germline BRCA-1/2 mutations. However, the current exploration of PARP inhibitors in breast cancer is still at early stage. This article summarizes the anticancer mechanism of PARP inhibitors and new advances in treatment of breast cancer.
